Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
Journal: The New England journal of medicine
Published: July 29, 2026
Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
Journal: Lancet (London, England)
Published: July 07, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Journal: The lancet. HIV
Published: March 17, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
Journal: Lancet (London, England)
Published: January 22, 2026
A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between Islatravir and Lenacapavir.
Journal: Journal of clinical pharmacology
Published: January 09, 2026
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
Journal: Annals of internal medicine
Published: December 22, 2025
Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: October 17, 2025
Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study.
Journal: Open forum infectious diseases
Published: August 05, 2025
Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV.
Journal: AIDS (London, England)
Published: April 07, 2025
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV.
Journal: AIDS and behavior
Published: January 09, 2025
Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.
Journal: AIDS (London, England)
Published: November 15, 2024
Effect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral Administration.
Journal: Clinical pharmacology in drug development
Published: October 30, 2024
Last Updated: 09/26/2026